Fagron Sa Ord (ARSUF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello. Good morning, everyone. Welcome to Fagron's First Quarter twenty twenty six Trading Update. I'm joined today by our CEO, Rafael Padilla and our CFO, Karim De Leon. We will open the floor for questions at the end of the session. With that, I will hand over to Rafael. Thank you, Ignacio, and good morning all. We're pleased to report a solid quarter with revenues of €263,000,000 representing 10.3% growth. Results were driven by outstanding performance in LatAm and strong contributions from our M and A. Brands continue to perform well across the board, supported by our innovation capabilities and commercial strategy. Operational excellence initiatives also continue to deliver benefits. During the quarter, we completed the acquisition of Pharmavit in The Netherlands and strengthening our position in the nutraceutical ingredients market. Also worth mentioning that Pharmavit integration together with all previously announced acquisition are progressing as planned. On guidance, we are maintaining our top line outlook of mid to high single digit organic growth at CR. On profitability, we expect a margin of circa 20% for the year, reflecting the Pharmavit acquisition. We also expect H2 to be stronger than H1. Moving on to the regional dynamics. EMEA reported a steady performance with all segments contributing. B and E performance was driven by innovative product launches and the continued rollout of our global brands strategy. Compounding services benefited from strong demand and new customer wins across the region. Turning to LatAm, we've seen an outstanding growth this quarter, mainly driven by brands in Brazil together with contributions from Pre Pharma and APACUM. Brands continue to deliver strong momentum driven by our innovation power and targeted commercial strat...